The company has demonstrably boosted its course of an innovative solution for amyloid heart disease, employing Attruby. Early trial BridgeBio data reveals significant improvements for individuals diagnosed by this debilitating condition. This focus represents BridgeBio's focus to managing critical healthcare requirements in the heart disease field.